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Abstract 
Although airway hyperresponsiveness (AHR) is a prominent feature of asthma, how it is 
regulated remains incompletely understood. Allergin-1, an inhibitory 
immunoglobulin-like receptor containing an immunoreceptor tyrosine-based inhibitory 
motif (ITIM), is expressed on human and mouse mast cells (MCs) and inhibits high 
affinity receptor for IgE (FcεRI)-mediated signaling. Using MC-deficient KitW-sh/W-sh 
mice and Mas–TRECK mice, which carries a diphtheria toxin (DT)-induced 
MC–deletion system based on il4 enhancer elements, we demonstrate here that MCs are 
involved in the induction of house dust mite (HDM)-induced AHR. Further, we show 
that MCs deficient in Allergin-1 exacerbated HDM-induced AHR, but had no effect on 
airway inflammation. In vitro analysis demonstrated that Allergin-1 inhibited anti-HDM 
allergen antibody-dependent HDM allergen-mediated degranulation by MCs. Thus, 
Allergin-1 on MCs plays an important role in the regulation of HDM-induced AHR.  
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Introduction: 
Airway hyperresponsiveness (AHR) causing airway obstruction is a prominent feature 
of asthma. Mast cells (MCs) infiltrated into the airways play an important role in AHR 
(1). MCs express the high-affinity receptor for IgE (FcεRI) that binds to an allergen 
through FcεRI-bound IgE. This interaction activates MCs, resulting in the secretion of a 
broad spectrum of pro-inflammatory cytokines, chemokines, and chemical mediators (2). 
IgE production by B cells is promoted by T helper 2 (Th2)-derived cytokines, IL-4, and 
anti-IgE therapy is beneficial in certain patients with severe asthma (3), suggesting that 
IgE-mediated signals in MCs play an important role in the pathogenesis of asthma. 
However, the role of MCs in the development of AHR is somewhat controversial (4), 
and the precise mechanisms by which MCs regulate AHR remain to be elucidated.  
Allergin-1, which is encoded by Milr1, is an inhibitory immunoglobulin-like 
receptor expressed on both human and mouse MCs (5,6). When Allergin-1 is co-ligated 
with IgE-bound FcεRI, tyrosine residues of immunoreceptor tyrosine-based inhibitory 
motif (ITIM) in the cytoplasmic region of Allergin-1 are phosphorylated and recruits the 
Src homology 2 domain–containing tyrosine phosphatases (SHP-1) and SHP-2, thereby 
blocking an early step in the activation signal mediated by FcεRI (5). 
Allergin-1–deficient mice show significantly enhanced passive systemic and cutaneous 
anaphylaxis, indicating that Allergin-1 suppresses IgE-mediated MC activation in vivo 
(5). Allergin-1 also inhibits toll-like receptor (TLR) 2-mediated activation of MCs in the 
skin and suppresses dermatitis (7).  
In this study, we examined the role of Allergin-1 on MCs in AHR and Th2 
responses in mice. We show that Allergin-1 regulated MC activation and suppressed 
AHR, but not Th2 responses, induced by house dust mite (HDM).
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Materials and Methods 
Animals 
Female BALB/cAJcl and C57BL/6N wild-type (WT) mice (8 to 12 weeks old) were 
purchased from Clea Japan (Tokyo, Japan). Allergin-1-deficient (Milr1–/–) mice on the 
BALB/c background were generated by backcrossing Milr1–/– C57BL/6N mice (5) to 
the BALB/cAJcl genetic background for 12 generations. KitW-sh/W-sh mice were provided 
by Riken BioResource Center (Tsukuba, Japan). Mas–TRECK mice on the BALB/c 
background have been previously described (8). All procedures were done according to 
the guidelines of the animal ethics committee of the University of Tsukuba (permit 
number 17-284). 
 
MC engraftment 
To generate bone marrow (BM)–derived cultured MCs (BMMCs), 2 × 106 BM cells 
were cultured in a 10-cm dish in complete RPMI 1640 medium (Sigma-Aldrich, St. 
Louis, MO, USA) containing 10% FBS (Life Technologies, Auckland, New Zealand) in 
the presence of 10 ng/mL stem cell factor (R&D Systems, Minneapolis, MN, USA) and 
4 ng/mL IL-3 (R&D Systems) for 4–5 weeks, at which time the cell population was 
composed of >95% MCs, as assessed with flow cytometry. Mas–TRECK mice were 
injected with diphtheria toxin (DT, 250 ng; Sigma-Aldrich) intraperitoneally 5 
consecutive days every 2 weeks to deplete endogenous MCs. On day 7 after the first 
injection of DT, 1 × 107 WT or Milr1–/– mice–derived BMMCs were injected 
intravenously into each DT-treated Mas–TRECK mouse. MCs reconstitution was 
assessed by flow cytometric analysis of peritoneal exudate MCs at 3 months after 
BMMCs injection. 
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HDM–induced allergic asthma model 
HDM allergen whole body extract (LSL Co., Ltd. Tokyo, Japan), derived from 
Dermatophagoides pteronyssinus (Der p), was used to induce allergic asthma. Animals 
were treated intranasally with 10 µg of HDM extract 5 consecutive days a week for 4 
weeks. Mice were assessed for airway hyperresponsiveness (AHR), airway 
inflammation, and serum IgE concentration 48 h after the last intranasal challenge.  
 
Measurement of airway hyperresponsiveness (AHR) to methacholine  
Airway resistances to different doses of aerosolized methacholine was measured by the 
computer-controlled piston ventilator system (FlexiVent, Montreal, Quebec, Canada) in 
accordance with the manufacturer’s instructions. Briefly, 48 hr after the last HDM 
challenge, mice were anesthetized, tracheotomized, and intubated intratracheally and 
exposed to an aerosol of 70 µl PBS (basal readings) and then of 70 µl methacholine in 
PBS at indicated concentration. Respiratory resistances were determined as the 
percentage change from the baseline index. 
 
Antibodies 
A monoclonal antibody (mAb) specific to mouse Allergin-1 (TX83; mouse IgG1) was 
generated in our laboratory, as described previously (5). TX83 was biotinylated with 
Biotinylation Kit (Sulfo-OSu; DOJIN, Tokyo, Japan). MAbs to mouse CD45.2 (104), 
c-Kit (2B8), Ly6G (1A8), CD11b (M1/70), CD11c (HL3), and Siglec-F (E50-2440) 
were purchased from BD Biosciences (San Joes, CA, USA); mAbs against CD16/32 
(2.4G2), FcεRI (MAR-1), CD3ε (145-2C11), and B220 (RA3-6B2) were purchased 
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from TONBO Bioscience (SanDiego, CA, USA); mAb against Gr-1 (RB6-8C5) and 
CD107a (1D4B) was purchased from BioLegend (SanDiego, CA, USA). 
 
Flow cytometric analysis of the lung and bronchoalveolar lavage fluid (BALF) cells 
The lung tissues were perfused with 1 ml of phosphate-buffered saline (PBS) through 
the right ventricle, removed, and digested with collagenase II (300 U/sample, 
Worthington Biochemical, Lakewood, NJ, USA) at 37°C for 1 h and dissociated with a 
gentleMACS Dissociator (B.01 program; Miltenyi Biotec, Auburn, CA). To assess the 
airway eosinophilia, bronchoalveolar lavage fluid (BALF) was harvested 48 h after the 
last HDM challenge and the trachea was cannulated with a 21G needle and plastic tube 
and washed with 1 mL of PBS 3 times. The cells were treated with anti-CD16/32 mAb 
to avoid binding to FcγR on ice for 10 min prior to incubation with indicated 
combination of antibodies. Propidium iodide (PI, 1 µg/ml; Sigma-Aldrich, St. Louis, 
MO, USA) was used to gate out dead cells. Cells were analyzed on a BD LSR Fortessa 
cell analyzer (BD Biosciences) and the FlowJo software program (Tree Star, San Carlos, 
CA, USA). 
 
Measurement of serum IgE concentration by ELISA 
For quantitation of serum levels of IgE, 96-well ELISA plates (NUNC Thermoscientific, 
Yokohama, Japan) were coated with rat anti-mouse IgE (catalog no. R35-72, BD 
Biosciences) diluted in 50 mM sodium bicarbonate buffer (pH 9.6) as a capture antibody. 
IgE was detected by using biotinylated anti-mouse IgE (catalog no. R35-118, BD 
Biosciences), followed by streptavidin-conjugated horseradish peroxidase (GE 
Healthcare Biosciences, Little Chalfont, UK). Mouse IgE (catalog no. C38-2, BD 
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Biosciences) was used as a standard. All of these assays were performed in accordance 
with the manufacturers’ instructions. 
 
Histology 
Forty-eight hours after the last HDM challenge, mice were anesthetized, and their lungs 
were harvested and fixed in 10% neutral buffered formalin. Fixed lungs were embedded 
in paraffin and stained with hematoxylin-eosin (HE) and periodic acid-Schiff (PAF). 
The goblet cell hyperplasia was assessed by measuring % area of the airway basement 
membrane that was positive for PAS staining in the total area of the airway basement 
membrane in randomly selected three bronchioles of each mice. Three mice per group 
were analyzed for the goblet cell hyperplasia. All images were acquired using a 
BZ-X710 microscope (Keyence, Osaka, Japan), and the data were analyzed using a 
BZ-H3 analyzer and Hybrid Cell Count (Keyence). 
 
Degranulation assay  
Degranulation was evaluated by a flow cytometric analysis of the cell-surface exposure 
of CD107a (LAMP-1). LAMP-1 is an intracellular protein found on granule membranes 
that becomes exposed on cell-surface upon degranulation (9). BMMCs were incubated 
for 20 h at 37 °C with serum obtained from a naïve mouse or from HDM-immunized 
mice (in which the serum IgE level was as high as 1 µg/ml) and then were stimulated 
for 30 min at 37 °C with the indicated concentrations of HDM extract. BMMCs were 
then stained with allophycocyanin (APC)-conjugated anti-CD107 and analyzed for the 
proportion of CD107a+ cells among c-Kit+ FcεRI+ cells by using flow cytometry. 
 
 8 
Statistics 
Statistical analyses were performed with the GraphPad Prism 7 software (La Jolla, CA, 
USA) by using the unpaired Student’s t-test or one-way or two-way ANOVA followed 
by Bonferroni’s multiple comparison test as a post-test. A P value less than 0.05 was 
considered statistically significant.  
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Results and discussion 
We first examined the involvement of MCs in HDM-induced AHR by using 
MC-deficient KitW-sh/W-sh mice. WT and KitW-sh/W-sh mice were immunized intranasally 
with 10 µg of HDM extract 5 consecutive days a week for 4 weeks (Fig. 1A). The 
airway eosinophilia and serum IgE level were comparable between the two groups (Fig. 
1B). However, AHR to methacholine was significantly decreased in KitW-sh/W-sh mice 
compared with that in WT mice (Fig. 1B), suggesting that MCs are responsible for 
HDM-induced AHR, but are dispensable for Th2 responses. To further demonstrate the 
function of MCs in HDM-induced AHR, we used diphtheria toxin (DT)-treated 
Mas–TRECK mice, an MC deletion system that uses Il4 enhancer elements (8). 
Although basophils are also depleted in DT-treated Mas–TRECK mice transiently, they 
quickly recovered within 3 days after the last DT treatment (8). In agreement with a 
previous report (8), flow cytometry did not detect MCs in the peritoneal cavity 2 days 
after the last injection of DT in Mas–TRECK mice (Fig. 1C and D). The DT-treated 
Mas–TRECK mice were reconstituted with WT bone marrow–derived cultured mast 
cells (BMMCs), and then repeatedly immunized with 10 µg of HDM extract by 
intranasal injection (Fig. 1C). The reconstitution of MCs was confirmed by analyzing 
the MC population in the peritoneal cavity 3 months after the BMMC transfer (Fig 1D). 
Although DT-treated Mas–TRECK mice, which lack MCs, were resistant to 
methacholine-induced AHR, the mice that had received WT BMMCs developed AHR in 
response to the challenge with methacholine (Fig. 1E). Collectively, these results 
indicate that MCs are responsible for HDM-induced AHR. 
We then examined the expression of Allergin-1 on MCs accumulated in the 
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lungs after HDM treatment. We found that the lung MCs (identified as 
CD45.2+Lin–CD11b+Siglec-F–FcεRI+c-Kit+ cells) highly expressed Allergin-1. In 
contrast, the lung eosinophils (indicated as CD45.2+Siglec-F+CD11bhigh cells) expressed 
undetectable level of Allergin-1 (Fig. 2A). The numbers of MCs in the lung were 
comparable between WT and Milr1–/– mice after HDM treatment (Fig. 2A). To 
investigate the role of Allergin-1 on MCs in HDM-induced AHR, we reconstituted 
DT-treated Mas–TRECK mice with BMMCs derived from either WT or Milr1–/– mice 
and treated them with HDM as shown in Fig. 1A. The reconstitution efficiency was 
comparable between WT and Milr1–/– BMMCs, as assessed by the MC population in the 
peritoneal cavity 3 months after the BMMC transfer (Fig. 2B). After the intranasal 
administration of HDM, the numbers of total cells (CD45+ cells) and eosinophils 
(CD45+Gr-1lowSiglec-F+CD11c– cells) in the bronchoalveolar lavage fluid (BALF) and 
the serum IgE levels were induced equally in both mouse populations, and no striking 
differences in goblet cell hyperplasia were observed between DT-treated Mas–TRECK 
mice that had been reconstituted with WT or Milr1–/– BMMCs (Fig. 2C–E). However, 
those mice reconstituted with Milr1–/– BMMCs showed more severe AHR to 
methacholine than did those reconstituted with WT BMMCs (Fig. 2F). Collectively, 
these results indicate that Allergin-1 on MCs is not involved in HDM-induced Th2 
responses but rather inhibits HDM-induced AHR.  
 AHR is considered to be triggered by chemical mediators, such as histamine, in 
the granules released from MCs (1). Therefore, we examined whether Allergin-1 
inhibits HDM allergen-induced degranulation from MCs. Since HDM-specific mouse 
IgE or IgG antibodies were unavailable, we used sera from HDM-immunized mice, in 
which the serum IgE level was as high as 1 µg/ml for HDM-induced degranulation from 
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MCs. WT or Milr1–/– BMMCs were sensitized overnight with the sera from either naïve 
or HDM-immunized mice, stimulated with HDM extract for 30 min, and then analyzed 
for CD107a expression on MCs (a marker of degranulation) by flow cytometry. After 
sensitization, Milr1–/– BMMCs had a larger population of CD107a+ cells than did WT 
BMMCs upon 1,000 ng/ml of HDM stimulation (Fig. 3A and B). In contrast, 
HDM-induced CD107a expression was scarcely detected on either genotype of BMMCs 
sensitized with naïve serum, demonstrating HDM allergen-induced MC degranulation 
requires sensitization of MCs with HDM-immunized sera. These results suggest that 
Allergin-1 inhibited anti-HDM antibody-dependent degranulation of MCs, thus 
suppressing HDM allergen-induced AHR.  
 The contribution of MCs in AHR has been controversial (4), because most 
previous studies on this issue used MC-deficient KitW-sh/W-sh or KitW/W-v mice and a 
virtual allergen, such as ovalbumin (OVA) with or without aluminum salt adjuvant 
(4,10). Those mice carry abnormalities due to c-Kit mutation in both hematopoietic and 
nonhematopoietic tissues as well as mast cells (11). Mas–TRECK mice used in this 
study show only the defect of MCs and basophils, and we reconstituted Mas–TRECK 
mice with BMMCs, thus more appropriate than mice with c-Kit mutation. Moreover, 
HDM is one of the commonest aeroallergens; more than 50% of allergic patients and up 
to 85% of asthmatics children are sensitized with HDM (12-14). Therefore, a mouse 
model using HDM as an allergen might be more appropriate for human asthma.  
A recent study by using mice deficient in IgE or FcεRIα demonstrated that 
HDM-induced AHR is independent of IgE and FcεRIα (15). In the current study, we 
showed that MCs were required for HDM-induced AHR in vivo and that MCs activation 
was dependent on the serum of HDM-immunized, but not naïve, mice in vitro, 
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suggesting that HDM-induced AHR was induced by MCs activated by anti-HDM 
antibody. However, we did not show the direct evidence for involvement of anti-HDM 
IgE antibody and FcεRIα. Since MC degranulation is also induced by the IgG immune 
complexes (16), it is also possible that MCs activation was mediated by the FcγRI, 
rather than FcεRIα, on MCs in our model. Further studies are required for understanding 
the mechanisms of HDM-induced AHR.  
We demonstrated that MCs play an important role in HDM-induced AHR. 
However, previous reports demonstrated that treatment with cysteine proteases, 
including papain, induce AHR, for which basophils and type 2 innate lymphoid cells 
(ILC2) are responsible (17,18). Cysteine proteases promote IL-4 production from 
basophils and activates ILC2, which augment inflammation via production of 
inflammatory cytokines and chemokines (17). Thus, basophil and ILC2-dependent AHR 
are involved in innate immune responses, whereas MCs-dependent AHR requires 
antibodies against HDM as results of adaptive immune responses. 
Because AHR is a fundamental pathology in asthma, control of AHR should be 
a therapeutic goal in the management of patients with asthma. Our findings show that 
MC is a key driver for AHR and that Allergin-1 on MCs plays a regulatory role in this 
process.  
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Figure 1. AHR in MC-deficient mice. (A and B) C57BL/6N WT (n = 4) and 
MC-deficient KitW-sh/W-sh mice (n = 4) were immunized intranasally with 10 µg of HDM 
extract 5 consecutive days a week for 4 weeks. (A) The experimental design (B) The 
proportion of eosinophils (CD45+CD11c–Siglec-F+) in the bronchoalveolar lavage fluid 
(BALF), serum IgE level, and AHR to methacholine were analyzed at 48 h after the last 
HDM immunization. (C-E) The experimental design (C). Three months after the 
BMMC injection, peritoneal exudate MCs in the naïve state from DT-non-treated, 
DT-treated (DT), and BMMC-reconstituted DT-treated (DT + BMMC) Mas–TRECK 
mice were analyzed by flow cytometry (D). DT-treated Mas–TRECK mice given no 
BMMCs (DT; n = 4) or reconstituted with WT-derived BMMCs (DT + BMMCs; n = 5) 
were immunized intranasally with 10 µg of HDM extract. AHR to methacholine was 
analyzed at 48 h after the last HDM immunization (E). Rrs, respiratory resistance. An 
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unpaired t-test was used to determine significant differences between the two groups. 
N.S., not significant. *, P < 0.05. Data are representative of at least 2 independent 
experiments (mean ± s.e.m.).  
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Figure 2. Allergin-1 on MCs suppresses AHR. (A) Flow cytometric analysis of MCs 
(CD45.2+Lin–Siglec-F–c-Kit+FcεRI+) and eosinophils (CD45.2+Lin–Siglec-F+CD11bhigh) 
in the lungs of WT and Milr1–/– mice after intranasal injection of HDM extract (100 
µg/mouse). Blue line, WT; red line, Milr1–/–; (right) Quantification of numbers of MCs. 
(B-F) DT-treated Mas–TRECK mice were injected with BMMCs derived from WT or 
Milr1–/– mice. (B) Three months after the BMMCs injection, the reconstitution capacity 
of the injected BMMCs was assessed in the peritoneal exudate cells by flow cytometry. 
(C-F) DT-treated MC-reconstituted Mas–TRECK mice were immunized with HDM 
extract as shown in Fig. 1C. (C) BALF and (D) blood samples collected 48 h after the 
last HDM challenge were analyzed for the numbers of total cells (CD45+) and 
eosinophils (CD45.2+Gr-1lowCD11c–Siglec-F+) and IgE concentration, respectively. (E) 
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Lungs were harvested 48 h after the last HDM challenge and analyzed for histology 
after treatment with hematoxylin-eosin (HE) and periodic acid-Schiff (PAS) staining. 
Original magnification: ×200. Right, quantification of PAS-positive goblet cells. (F) 
AHR to methacholine. DT-treated Mas–TRECK mice given no BMMCs (n = 3) or 
reconstituted with BMMCs from WT (n = 4) or Milr1–/– (n = 5) were immunized with 
HDM extract. Forty-eight hours after the last HDM challenge, AHR to methacholine 
was analyzed. Data are representative of 3 (C – E) or 2 (A, B and F) independent 
experiments (mean ± s.e.m.). Each point represents a single mouse. N.S., not significant. 
*, P < 0.05 (WT vs Milr1–/–, unpaired t-test).  
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Figure 3. Allergin-1 on MCs inhibits anti-HDM antibody-dependent degranulation. 
WT or Milr1–/– BMMCs were treated for 16 h with serum from naïve or HDM-treated 
mice, followed by HDM extract stimulation for 30 min, and analyzed for degranulation 
by CD107a expression. (A) representative results by flow cytometric analysis. (B) 
Statistical analysis. ***, P < 0.005; ****, P < 0.001 (WT vs Milr1–/–, unpaired t-test). 
Data are representative of 3 independent experiments (mean ± s.e.m.).  
 
 
 
 
